36.67 % to Target, H.C. Wainwright Maintains ‘Buy’ Rating on Aptose Biosciences (NASDAQ:APTO) Shares Today

June 19, 2018 - By Duane Lopez

Aptose Biosciences (NASDAQ:APTO) Rating Reaffirmed

H.C. Wainwright now has a $6.0000 target on shares of Aptose Biosciences (NASDAQ:APTO). The target would indicate a potential upside of 36.67 % from the stock close price of Aptose Biosciences (NASDAQ:APTO). This rating was released in an analyst note on Friday, 15 June.

Aptose Biosciences Inc. (NASDAQ:APTO) Ratings Coverage

Among 2 analysts covering Aptose Biosciences (NASDAQ:APTO), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aptose Biosciences has $600 highest and $600 lowest target. $6’s average target is 36.67% above currents $4.39 stock price. Aptose Biosciences had 5 analyst reports since March 28, 2018 according to SRatingsIntel. The company was maintained on Monday, April 16 by H.C. Wainwright. Roth Capital maintained Aptose Biosciences Inc. (NASDAQ:APTO) rating on Monday, April 16. Roth Capital has “Buy” rating and $600 target. The firm has “Buy” rating given on Wednesday, March 28 by H.C. Wainwright. The rating was maintained by Roth Capital on Tuesday, June 5 with “Buy”. The firm has “Buy” rating by H.C. Wainwright given on Monday, May 7.

The stock decreased 2.44% or $0.11 during the last trading session, reaching $4.39. About 781,889 shares traded or 104.92% up from the average. Aptose Biosciences Inc. (NASDAQ:APTO) has risen 252.94% since June 20, 2017 and is uptrending. It has outperformed by 240.37% the S&P500.

Analysts await Aptose Biosciences Inc. (NASDAQ:APTO) to report earnings on August, 14. They expect $-0.17 earnings per share, down 54.55 % or $0.06 from last year’s $-0.11 per share. After $-0.23 actual earnings per share reported by Aptose Biosciences Inc. for the previous quarter, Wall Street now forecasts -26.09 % EPS growth.

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. The company has market cap of $148.48 million. The Company’s lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. It currently has negative earnings. The firm has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma.

More notable recent Aptose Biosciences Inc. (NASDAQ:APTO) news were published by: Nasdaq.com which released: “Aptose Presents New CG-806 Data at the 23rd Congress of the European Hematology Association” on June 15, 2018, also Benzinga.com with their article: “Benzinga Pro’s 5 Stocks To Watch Today” published on June 14, 2018, Seekingalpha.com published: “Aptose secures rights to blood cancer candidate in China from CrystalGenomics for up to $125M; shares up 9 …” on June 14, 2018. More interesting news about Aptose Biosciences Inc. (NASDAQ:APTO) were released by: Nasdaq.com and their article: “Aptose Announces Two Publications of Preclinical Data Elucidating the Anticancer Mechanism of Action of APTO-253” published on June 04, 2018 as well as Benzinga.com‘s news article titled: “Benzinga’s Daily Biotech Pulse: Biohaven Sells Right To Drug, Obseva To Sell Shares” with publication date: June 19, 2018.

Aptose Biosciences Inc. (NASDAQ:APTO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: